Madrigal Pharmaceuticals, Inc.
MDGLNASDAQHealthcareBiotechnology
Previous close
$516.74
−$2.35 · -0.45%
MDGL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
93
Deep Value
Momentum
60
Neutral
Sentiment
55
Mixed
Risk resilience
67
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMadrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- William J. Sibold
- Listed since
- Feb 6, 2007
- Employees
- 915
Market position
Day range
Current $516.74
52-week range
Current $516.74
- Open
- $523.1
- Previous close
- $519.09
- Volume
- 179.83K
- 0.54× average
- Average volume
- 335.43K
- Average daily volume
- Market cap
- 11.94B USD
- Beta
- -1
- Market reference 1
- 50-day average
- $522.83
- -1.16% below average
- 200-day average
- $513.86
- +0.56% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 13.22B USD
- EV / EBITDA
- -49.99×
- Earnings yield
- -2.21%
- Free cash flow yield
- -1.45%
Profitability & efficiency
- Return on equity
- -47.83%
- Return on assets
- -22.89%
- Return on invested capital
- -31.58%
Financial health
- Current ratio
- 4.01×
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
MDGL peers
ETFs holding MDGL
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI274.26M0.01%2.3T USD0.03%$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB198.2M0.11%183.4B USD0.03%$304.76+0.64%
State Street SPDR S&P Biotech ETFXBI114.79M1.01%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Small-Cap Growth ETFVBK114.73M0.26%43.8B USD0.05%$358.65+0.70%
Vanguard Extended Market ETFVXF101.7M0.11%93.7B USD0.05%$245.53+0.82%
First Trust NYSE Arca Biotechnology Index FundFBT87.16M3.00%2.94B USD0.55%$271.07+1.10%
iShares Biotechnology ETFIBB84.2M0.79%10.75B USD0.44%$213.56+1.29%
iShares Russell Mid-Cap Growth ETFIWP53.51M0.26%20.62B USD0.23%$143.66+0.99%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 274.26M
- Weight
- 0.01%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 198.2M
- Weight
- 0.11%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
State Street SPDR S&P Biotech ETFXBI- Market value
- 114.79M
- Weight
- 1.01%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Small-Cap Growth ETFVBK- Market value
- 114.73M
- Weight
- 0.26%
- AUM
- 43.8B USD
- Expense ratio
- 0.05%
- Price / 1D
- $358.65+0.70%
Vanguard Extended Market ETFVXF- Market value
- 101.7M
- Weight
- 0.11%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
First Trust NYSE Arca Biotechnology Index FundFBT- Market value
- 87.16M
- Weight
- 3.00%
- AUM
- 2.94B USD
- Expense ratio
- 0.55%
- Price / 1D
- $271.07+1.10%
iShares Biotechnology ETFIBB- Market value
- 84.2M
- Weight
- 0.79%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
iShares Russell Mid-Cap Growth ETFIWP- Market value
- 53.51M
- Weight
- 0.26%
- AUM
- 20.62B USD
- Expense ratio
- 0.23%
- Price / 1D
- $143.66+0.99%
Continue in GoAI
Research MDGLresearch.disclaimer